Maria Bedoya Toro Munera Biography and Net Worth

Senior Vice President of Regulatory Affairs and Quality Assurance of Dermata Therapeutics


Maria Bedoya Toro Munera, Ph.D., M.B.A. became our Senior Vice President of Regulatory Affairs and Quality Assurance in January 2016. Dr. Bedoya Toro Munera has more than 30 years of experience in regulatory compliance, quality control and quality assurance within the pharmaceutical industry. From 2014 until its sale to Celgene in 2015, Dr. Bedoya Toro Munera served as Senior Vice President, Regulatory Affairs and Quality Assurance at Receptos Inc. Prior to Receptos, Inc., Dr. Bedoya Toro Munera served as Senior Vice President of Regulatory Affairs and Quality Assurance at Santarus, Inc. from June 2007 to January 2014. She previously served as Senior Director Regulatory Affairs at Eisai Medical Research Inc., from November 2006 to May 2007, moving to Eisai from Ligand Pharmaceuticals, Inc. when Ligand divested their oncology products to Eisai in November 2006. Dr. Bedoya Toro Munera worked as Senior Director Global Regulatory Affairs and Compliance at Ligand from 2003 to 2006. From 2000 to 2003, she served as Director Global Regulatory Affairs at Baxter Hyland Immuno. From 1998 to 2000, Dr. Bedoya Toro Munera worked at BASF Bioresearch Corporation as Director, Regulatory Affairs/Quality, and from 1996 to 1998, she worked as Director, Quality Assurance and Regulatory Compliance at Amylin Pharmaceuticals. From 1988 to 1996, Dr. Bedoya Toro Munera worked at Rhone-Poulenc Rorer in a number of increasingly responsible positions in regulatory compliance, quality assurance, quality control and compliance. Dr. Bedoya Toro Munera holds an M.B.A. from the University of Chicago, and a Ph.D. in bio-analytical chemistry from Ohio University. In addition, she has a M.A. in bio-analytical chemistry and a B.S. in chemistry from Western Michigan University.

What is Maria E. Bedoya Toro Munera's net worth?

The estimated net worth of Maria E. Bedoya Toro Munera is at least $1.07 thousand as of February 17th, 2026. Dr. Bedoya Toro Munera owns 1,012 shares of Dermata Therapeutics stock worth more than $1,073 as of October 9th. This net worth approximation does not reflect any other assets that Dr. Bedoya Toro Munera may own. Learn More about Maria E. Bedoya Toro Munera's net worth.

How do I contact Maria E. Bedoya Toro Munera?

The corporate mailing address for Dr. Bedoya Toro Munera and other Dermata Therapeutics executives is 3525 Del Mar Heights RD., #322, San Diego, CA, 92130. Dermata Therapeutics can also be reached via phone at 858-800-2543 and via email at [email protected]. Learn More on Maria E. Bedoya Toro Munera's contact information.

Has Maria E. Bedoya Toro Munera been buying or selling shares of Dermata Therapeutics?

Maria E. Bedoya Toro Munera has not been actively trading shares of Dermata Therapeutics in the last ninety days. Most recently, on Tuesday, February 17th, Maria E. Bedoya Toro Munera bought 1,000 shares of Dermata Therapeutics stock. The stock was acquired at an average cost of $1.27 per share, with a total value of $1,270.00. Following the completion of the transaction, the senior vice president now directly owns 1,012 shares of the company's stock, valued at $1,285.24. Learn More on Maria E. Bedoya Toro Munera's trading history.

Are insiders buying or selling shares of Dermata Therapeutics?

During the last year, Dermata Therapeutics insiders bought shares 1 times. They purchased a total of 1,000 shares worth more than $1,270.00. The most recent insider tranaction occured on February, 17th when SVP Maria E. Bedoya Toro Munera bought 1,000 shares worth more than $1,270.00. Insiders at Dermata Therapeutics own 21.9% of the company. Learn More about insider trades at Dermata Therapeutics.

Information on this page was last updated on 2/17/2026.

Maria E. Bedoya Toro Munera Insider Trading History at Dermata Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/17/2026Buy1,000$1.27$1,270.001,012View SEC Filing Icon  
See Full Table

Maria E. Bedoya Toro Munera Buying and Selling Activity at Dermata Therapeutics

This chart shows Maria E. Bedoya Toro Munera's buying and selling at Dermata Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Dermata Therapeutics Company Overview

Dermata Therapeutics logo
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $1.06
Low: $1.05
High: $1.10

50 Day Range

MA: $1.24
Low: $1.06
High: $1.72

2 Week Range

Now: $1.06
Low: $0.95
High: $4.84

Volume

6,963 shs

Average Volume

22,773 shs

Market Capitalization

$4.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.66